Tcr2 Therapeutics Analysis
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
Tcr2 Therapeutics is overvalued with Real Value of 1.35 and Hype Value of 1.48. The main objective of Tcr2 Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Tcr2 Therapeutics is worth, separate from its market price. There are two main types of Tcr2 Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Tcr2 Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tcr2 Therapeutics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Tcr2 Stock trading window is adjusted to America/New York timezone.
Tcr2 |
Tcr2 Stock Analysis Notes
About 54.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tcr2 Therapeutics recorded a loss per share of 4.2. The entity had not issued any dividends in recent years. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Tcr2 Therapeutics contact Dr MBA at 617 949 5200 or learn more at https://www.tcr2.com.Tcr2 Therapeutics Investment Alerts
| Tcr2 Therapeutics is not yet fully synchronised with the market data | |
| Tcr2 Therapeutics may become a speculative penny stock | |
| Tcr2 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (151.82 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tcr2 Therapeutics currently holds about 175.99 M in cash with (101.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Tcr2 Therapeutics Upcoming and Recent Events
| 14th of August 2023 Upcoming Quarterly Report | View | |
| 14th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Tcr2 Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 58.11 M.Tcr2 Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tcr2 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tcr2 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tcr2 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mpm Sunstates Fund Lp over a year ago Acquisition or disposition of Tcr2 Therapeutics securities by Mpm Sunstates Fund Lp | ||
Peter Olagunju over a year ago Disposition of 24092 shares by Peter Olagunju of Tcr2 Therapeutics subject to Rule 16b-3 | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 50000 shares of Tcr2 Therapeutics | ||
Mpm Asset Management Llc over a year ago Exercise of in-the-money or at-the-money derivative position by Mpm Asset Management Llc of 135508 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 38765 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Purchase by Tang Kevin C of 57073 shares of Tcr2 Therapeutics | ||
Tang Kevin C over a year ago Tcr2 Therapeutics exotic insider transaction detected |
Tcr2 Therapeutics Outstanding Bonds
Tcr2 Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tcr2 Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tcr2 bonds can be classified according to their maturity, which is the date when Tcr2 Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US878091BD86 Corp BondUS878091BD86 | View | |
| US878091BG18 Corp BondUS878091BG18 | View | |
| US878091BF35 Corp BondUS878091BF35 | View | |
| US878091BC04 Corp BondUS878091BC04 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Tcr2 Therapeutics Predictive Daily Indicators
Tcr2 Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tcr2 Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Tcr2 Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Tcr2 Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tcr2 shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Tcr2 Therapeutics. By using and applying Tcr2 Stock analysis, traders can create a robust methodology for identifying Tcr2 entry and exit points for their positions.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Tcr2 Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Aroon Oscillator Now
Aroon OscillatorAnalyze current equity momentum using Aroon Oscillator and other momentum ratios |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |